A preliminary report of a phase II study of weekly topotecan in platinum-sensitive recurrent ovarian and peritoneal carcinoma

被引：0
|
作者：
Rodriguez, M
Method, MW
Lewandowski, G
Vaccarello, L
Ansari, RH
机构：
[1] Gynecol Oncol & Pelv Surg Associates, Columbus, OH USA
[2] Michiana Hematol Oncol, South Bend, IN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5063
引用
收藏
页码：464S / 464S
页数：1
相关论文
共 50 条
  • [41] Phase 2 study of weekly triplet regimen of docetaxel, carboplatin and gemcitabine in recurrent platinum-sensitive epithelial ovarian cancer.
    Salimichokami, M
    Vahid, AA
    Mir, MR
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 486S - 486S
  • [42] Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study
    Ferrandina, G.
    Ludovisi, M.
    De Vincenzo, R.
    Salutari, V.
    Loruss, D.
    Colangelo, M.
    Prantera, T.
    Valerio, M. R.
    Scambia, G.
    ANNALS OF ONCOLOGY, 2007, 18 (08) : 1348 - 1353
  • [43] Phase II Study of Pegylated Liposomal Doxorubicin and Carboplatin in Patients With Platinum-Sensitive and Partially Platinum-Sensitive Metastatic Ovarian Cancer
    Rapoport, B. L.
    Vorobiof, D. A.
    Slabber, C.
    Alberts, A. S.
    Hlophe, H. S.
    Mohammed, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (06) : 1137 - 1141
  • [44] Management of platinum-sensitive recurrent ovarian cancer
    Pfisterer, Jacobus
    Ledermann, Jonathan A.
    SEMINARS IN ONCOLOGY, 2006, 33 (02) : S12 - S16
  • [45] Phase 1 and 2 Study of Carboplatin and Pralatrexate in Patients With Recurrent, Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    del Carmen, Marcela G.
    Supko, Jeff G.
    Horick, Nora K.
    Rauh-Hain, J. Alejandro
    Clark, Rachel M.
    Campos, Susana M.
    Krasner, Carolyn N.
    Atkinson, Tina
    Birrer, Michael J.
    CANCER, 2016, 122 (21) : 3297 - 3306
  • [46] Phase II Evaluation of Nanoparticle Albumin-Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
    Teneriello, Michael G.
    Tseng, Paul C.
    Crozier, Mark
    Encarnacion, Carlos
    Hancock, Kenneth
    Messing, Mark J.
    Boehm, Kristi A.
    Williams, Alicia
    Asmar, Lina
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) : 1426 - 1431
  • [47] Phase I/II study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer.
    Chelariu-Raicu, Anca
    Levenback, Charles F.
    Slomovitz, Brian M.
    Bodurka, Diane C.
    Gershenson, David Marc
    Coleman, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Phase II open label randomized study of trabectedin (T) given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: Preliminary results.
    Del Campo, J.
    Roszak, A.
    Ciuleanu, T.
    Bidzinski, M.
    Hogberg, T.
    Wojtukienicz, M.
    Boman, K.
    Poveda, A.
    Westermann, A.
    Izquierdo, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 263S - 263S
  • [49] Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer
    Matulonis, Ursula
    Berlin, Suzanne
    Lee, Hang
    Whalen, Christin
    Obermayer, Elizabeth
    Penson, Richard
    Liu, Joyce
    Campos, Susana
    Krasner, Carolyn
    Horowitz, Neil
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (02) : 417 - 423
  • [50] The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer
    Gubbi, Ajit
    Kendrick, James E.
    Finkler, Neil J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (10) : 1105 - 1113
12345